Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Go back to Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics, Inc. (CVKD) Tops Q3 EPS by 8c

November 10, 2025 9:05 AM EST

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q3 EPS of ($1.31), $0.08 better than the analyst estimate of ($1.39).

For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.

... More